AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects

High glutamine suppresses osteogenesis through mTORC1-mediated inhibition of the mTORC2/AKT-473/RUNX2 axis

(2022) Meher Bolisetti Gayatri et al.   Cell Death Discovery

Metabolic alterations mediated by STAT3 promotes drug persistence in CML

(2021) Sweta B. Patel et al.   LEUKEMIA

RUNX1 Upregulates CENPE to Promote Leukemic Cell Proliferation

(2021) Shan Liu et al.   Frontiers in Molecular Biosciences

RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses

(2020) Shady Adnan Awad et al.   LEUKEMIA

Analysis of cellular models of clonal evolution reveals co-evolution of imatinib and HSP90 inhibitor resistances

(2020) Rajender Goud Arolla et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling

(2019) Maja Kim Kuepper et al.   LEUKEMIA

Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update

(2019) Luana Bavaro et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A novel phosphorylation by AMP-activated kinase regulates RUNX2 from ubiquitination in osteogenesis over adipogenesis

(2018) Suresh Chava et al.   Cell Death & Disease

Runx1-Stat3-Tgfb3 signaling network regulating the anterior palatal development

(2018) Safiye E. Sarper et al.   Scientific Reports

RUNX1-Evi-1 fusion gene inhibited differentiation and apoptosis in myelopoiesis: an in vivo study

(2015) Lijing Shen et al.   BMC CANCER

Silencing of Suppressor of Cytokine Signaling-3 due to Methylation Results in Phosphorylation of STAT3 in Imatinib Resistant BCR-ABL Positive Chronic Myeloid Leukemia Cells

(2014) Hamid AN Al-Jamal et al.   Asian Pacific Journal of Cancer Prevention

Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia

(2014) André L Mencalha et al.   BMC CANCER

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia

(2014) A M Eiring et al.   LEUKEMIA

A novel recurrent AML1–ETO fusion: tight in vivo association with BCR–ABL1

(2013) L Solari et al.   LEUKEMIA

Functionally Deregulated AML1/RUNX1 Cooperates with BCR-ABL to Induce a Blastic Phase-Like Phenotype of Chronic Myelogenous Leukemia in Mice

(2013) Kiyoko Yamamoto et al.   PLoS One

Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia

(2012) L.-J. Zhao et al.   BLOOD

Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer

(2012) Cornelia Johanna Franziska Scheitz et al.   EMBO JOURNAL

Role of STAT3 in Transformation and Drug Resistance in CML

(2012) Rajesh R. Nair et al.   Frontiers in Oncology

Antileukemic effects of AMPK activators on BCR-ABL-expressing cells

(2011) E. Vakana et al.   BLOOD

Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor

(2011) M. S. Redell et al.   BLOOD

Deactivation of Signal Transducer and Activator of Transcription 3 Reverses Chemotherapeutics Resistance of Leukemia Cells via Down-Regulating P-gp

(2011) Xulong Zhang et al.   PLoS One

IFNγ-dependent SOCS3 expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cells

(2010) Hans A. R. Bluyssen et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate

(2010) X. Jiang et al.   BLOOD

Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance

(2008) Nadine N. Bewry et al.   MOLECULAR CANCER THERAPEUTICS